Status:

COMPLETED

Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery

Lead Sponsor:

Tanta University

Conditions:

Dexmedetomidine

Lidocaine 5% Patch

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Surgery of the knee is a very common procedure which can be very painful and sufficient postoperative pain treatment is often problematic. The aim of this work was to study the effects of supplementat...

Eligibility Criteria

Inclusion

  • Adult patients
  • ASA I \& II
  • Aged between 18 to 60 years
  • Weight between 60 to 100 kg
  • Scheduled for elective arthroscopic knee surgery

Exclusion

  • patient refusal.
  • history of cardiac disease.
  • impaired renal or hepatic function.
  • hypertension treated with α methyldopa, clonidine, or beta-adrenergic blockers.
  • if they have used opioid analgesics within the previous 24 hr.
  • previous sensitivity to local anesthetics.

Key Trial Info

Start Date :

December 1 2016

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

December 1 2017

Estimated Enrollment :

40 Patients enrolled

Trial Details

Trial ID

NCT04322760

Start Date

December 1 2016

End Date

December 1 2017

Last Update

March 27 2020

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

Lidocaine 5% Patch Supplementation to Intra-articular Bupivacaine Dexmedetomidine After Arthroscopic Knee Surgery | DecenTrialz